| Registration number |
Name of drug |
Indication |
Popular trial subject |
CTR20230825
NCT05816252 |
SKB264 for Injection |
NSCLC |
Phase 2 clinical study of SKB264 monotherapy or combination therapy for advanced or metastatic NSCLC patients |
CTR20231535
NCT05870319 |
SKB264 for Injection |
Locally advanced or metastatic NSCLC with EGFR mutations that have failed treatment with EGFR-TKI |
A phase 3 study on the efficacy of SKB264 monotherapy compared to the combination of pemetrexed and platinum-based therapy in locally advanced or metastatic NSCLC with EGFR mutations that have failed treatment with EGFR-TKI |
CTR20201069
NCT04152499 |
SKB264 for Injection |
Solid tumor |
SKB264 Phase 1-2 Trial in patients with locally advanced or metastatic solid tumors |
CTR20220878
NCT05347134 |
SKB264 for Injection |
Triple-negative breast cancer |
Phase 3 trial of SKB264 for patients with locally advanced, relapsed or metastatic triple-negative breast cancer who received at least 2L setting
|
CTR20220980
NCT05351788 |
SKB264 for Injection |
locally advanced or metastatic non-small cell lung cancer |
Phase 2 clinical research of SKB264 combination therapies in patients with advanced or metastatic non-small cell lung cancer
|
CTR20221755
NCT05445908 |
SKB264 for Injection |
HER2-negative Breast Cancer |
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
|
CTR20222948
NCT05631262 |
SKB264 for Injection |
Advanced solid tumors |
Multi-center and open Phase 2 research to evaluate effectiveness and safety of SKB264 monotherapy in selected patient with advanced solid tumors |
CTR20223165
NCT05642780 |
SKB264 for Injection |
Solid Tumors |
A basket study to evaluate effectiveness and safety of SKB264 in combination with Pembrolizumab in subjects for solid tumors
|
CTR20232807
NCT06081959 |
SKB264 for Injection |
HR+/HER2-breast cancer |
A Randomized, Open-label, Multicenter Phase 3 Study of SKB264 Versus Treatment of Physician's Choice (TPC) in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy |
CTR20240413
NCT06279364 |
SKB264 for Injection |
Triple-negative breast cancer |
A Randomized, Open-Label, Multicenter Phase III Study of SKB264 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
|
CTR20241364
NCT06448312 |
SKB264 for Injection |
PD-L1-positive locally advanced or metastatic non-small cell lung cancer |
A randomized, open-label, multicenter phase III clinical study of SKB264 combined with pembrolizumab versus pembrolizumab as first-line treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer
|
CTR20243435
NCT06711900 |
SKB264 for Injection |
Advanced or metastatic non-small cell lung cancer |
A randomized, open-label, multicenter phase III clinical study of SKB264 combined with pembrolizumab versus chemotherapy combined with pembrolizumab as first-line treatment for patients with PD-L1-negative locally advanced or metastatic non-squamous non-small cell lung cancer
|
CTR20243986
NCT06670196 |
SKB264 for Injection |
Non-small cell lung cancer |
A randomized, open-label, multicenter phase III clinical study of SKB264 combined with osimertinib versus osimertinib as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations
|
| CTR20231740 |
A166 for Injection |
HER2-positive unresectable or metastatic breast cancer |
A randomized, open-label, controlled trial of A166 for injection versus trastuzumab emtansine for injection (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who were previously treated with trastuzumab and taxanes , Multicenter phase III clinical trial |
CTR20181301
NCT05311397 |
A166 for Injection |
HER2 expression locally advanced or metastatic solid tumor |
Phase 1 clinical study on the safety and tolerability of A166 injectable solution |
| CTR20212950 |
A166 for Injection |
HER2-positive Advanced malignant solid tumors |
Phase 1b clinical trial of A166 for injection for patients with HER2-positive Colorectal Cancer |
| CTR20213396 |
A166 for Injection |
Gastric cancer or GEJ cancer |
Open and multi-center Phase 1b clinical trial of A166 for injection in patients with HER2-positive locally advanced or metastatic gastric cancer or GEJ cancer |
| CTR20212088 |
A166 for Injection |
Breast cancer |
Phase 2 clinical research of A166 for injection in end-stage HER2+ BC patients
|
| CTR20242261 |
A166 For Injection |
HER2-positive unresectable or metastatic breast cancer |
An open, multicenter phase II clinical study of A166 for injection in the treatment of HER2 positive unresectable or metastatic breast cancer that previously received overload as the drug conjugate of topoisomerase inhibitor antibody (ADC)
|
CTR20220285
NCT05367635 |
SKB315 for Injection |
Advanced solid tumors with CLDN18.2 expression |
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients with Advanced Solid Tumors Expressing CLDN18.2 |
CTR20231276
NCT05906537 |
SKB410 for Injection |
Advanced solid tumors |
Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SKB410 injection for the treatment of advanced solid tumors in subjects
|
CTR20242227
NCT06428331 |
SKB518 for injection |
Advanced solid tumors |
Phase I clinical study on the safety, tolerability, pharmacokinetics, and anti-tumor activity of SKB518 for injection in patients with advanced solid tumors
|
CTR20244431
NCT06726369 |
SKB535 for injection |
Advanced solid tumors |
Phase I clinical trial of SKB535 for injection in advanced solid tumors
|
CTR20244432
NCT06725381 |
SKB571 for injection |
Solid tumors |
Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SKB571 injection for the treatment of advanced solid tumors in subjects
|
CTR20244608
NCT06736327 |
SKB500 for injection |
Advanced solid tumors |
Phase I clinical study on the safety, tolerability, pharmacokinetics, and anti-tumor activity of SKB500 injection in the treatment of advanced solid tumor subjects
|
CTR20250240
NCT06826040 |
SKB445 for injection |
Advanced solid tumors |
SKB445 for Injection in Solid Tumors
|
CTR20220691
NCT05294172 |
KL-A167 for Injection |
Recurrent or metastatic nasopharyngeal carcinoma |
Phase 3 clinical research of injectable KL-A167 in patients withrecurrent or metastatic nasopharyngeal carcinoma |
CTR20190152
NCT03848286 |
KL-A167 for Injection |
Relapsed or refractory nasopharyngeal cancer |
Phase 2 clinical research of Injectable KL-A167 in patients with relapsed or metastatic nasopharyngeal cancer |
| CTR20181198 |
KL-A167 for Injection |
Advanced solid tumors |
Phase 1a research of injectable KL-A167 for advanced solid tumors
|
CTR20202451
NCT04835142 |
Recombinant Chimeric Anti-EGFR Monoclonala Antibody For Injection |
RAS wild-type metastatic colorectal cancer |
Phase 3 clinical research to compare effectiveness and safety of each of A140 and Erbitux® in combination with mFOLFOX6 as a first-line treatment option in patients with RAS wild-type metastatic colorectal cancer |
| CTR20240403 |
KL590586 Capsules |
Advanced solid tumors harboring RET fusions or mutations |
Study on drug interaction of KL590586 for capsules
|
| CTR20232608 |
KL590586 Capsules |
Advanced solid tumors harboring RET fusions or mutations |
To evaluate the randomized, open-label, two-cycle, double-cross food effects of KL590586 capsules in healthy subjects in a phase I clinical trial |
CTR20211547
NCT05265091 |
KL590586 for Capsule |
Advanced solid tumors with RET gene fusions or mutations |
Assess safety, tolerability and pharmacokinetic of KL590586 capsule in advanced solid tumors patients with RET gene fusions or mutations |
| CTR20232730 |
KL590586 Capsules |
Advanced solid tumors harboring RET fusions or mutations |
Study on material balance and biotransformation of KL590586 capsules |
CTR20220985
NCT05387928 |
KL340399 for Injection |
Advanced solid tumors |
Phase 1 Clinical Study to Evaluate the Safety, Tolerability,Pharmacokinetics and Preliminary Efficacy of KL340399 Injection in Patients With Advanced Solid Tumors
|
CTR20221772
NCT05549804 |
KL340399 for Injection |
Advanced solid tumors |
Phase 1 clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KL340399 Intratumoral in Patients With Advanced Solid Tumors |
| CTR20202664 |
KL130008 for Capsule |
Rheumatoid arthritis |
Research to evaluate efficacy and safety of KL130008 capsule for mild or moderate activity rheumatoid arthritis patients |
CTR20221881
NCT05496426 |
KL130008 for Capsule |
Severe alopecia areata |
Clinical research to evaluate safety and effectiveness of KL130008 capsule |
| CTR20230853 |
KL130008 Capsule (new prescription drug) |
Healthy subjects |
Randomized, open, two-period, two-sequence, and double-crossover Phase 1 clinical research to evaluate bioequivalence and food effects of KL130008 capsule in healthy subjects
|
| CTR20181763 |
KL130008 for capsule |
Rheumatoid Arthritis |
Phase 1 research of safety and tolerability of KL130008 capsule in healthy subjects
|
| CTR20191446 |
KL130008 for capsule |
Rheumatoid Arthritis |
Phase 1 clinical research of tolerability and PK/PD of KL130008 capsule in patients with rheumatoid arthritis
|
| CTR20211299 |
KL130008 for Capsule |
Rheumatoid Arthritis |
Research to evaluate efficacy and safety of KL130008 capsule in mild or moderate activity rheumatoid arthritis patients |
| CTR20222274 |
KL280006 for Injection |
Uremic pruritus |
Research to evaluate effectiveness and safety of Injectable KL280006 in patients on hemodialysis with moderate-to-severe uremic pruritus
|
CTR20221961
NCT05790694 |
HBM9378（SKB378）for Injection |
Asthma |
Phase 1 clinical research in Chinese healthy subjects of randomized, double-blind, placebo-controlled, single-dose and dose expansion to evaluate safety and pharmacokinetic of HBM9378(SKB378) following subcutaneous injection for dosing |
| CTR20211808 |
SKB336 for Injection |
Prevention and treatment of thromboembolic disorders |
Phase 1a clinical research of safety, tolerability and pharmacokinetic of injectable SKB336 in healthy patients |
